Zeria Pharmaceutical Co., Ltd.
TTSE:45592,024.00
JPY
+19.00
(+0.95%)
ISIN
JP3428850006
Return %
Stock
S&P 500
1Y
0.30
14.20
3Y
0.80
81.12
5Y
-0.49
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Sachiaki Ibe
- Full Time Employees
- 1,748
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 10-11 Nihonbashi Kobuna-cho Tokyo TK Japan 103-8351
- IPO Date
- Dec 22, 1998
- Website
- zeria.co.jp
- Similar Companies
- Business
- Zeria Pharmaceutical Co., Ltd. (4559.T) manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents; cosmetics; health foods; alcoholic beverages; soft drinks; food additives; livestock feed; hygienic goods; medical devices; health equipment; hygiene facilities and equipment; beauty appliances; and measuring and analytical equipment. The company, founded in December 1955 and headquartered in Tokyo, Japan, specializes in ethical drugs primarily for gastroenterology including therapeutic agents for functional dyspepsia (Acofide), ulcerative colitis and Crohn's disease (Asacol), gastritis and ulcers (Promac), oral bowel cleansing agents (Visiclear), laxatives (WithOne), hypophosphatemia (Phosribbon), iron deficiency anemia (Ferinject), hyperkalemia (Veltassa), and proton pump inhibitors; long-acting calcium channel blockers (Landel); oral NSAIDs (Peon); anti-leukopenia products (Ancer); anti-inflammatory topical agents; non-steroidal anti-inflammatory ophthalmic solutions; zinc-containing anti-ulcerants; consumer healthcare products such as nutritional health drugs (Hepalyse, Chondroitin ZS Tablets), gastrointestinal remedies (Acinon Z, Stomacool), western herbal medicines, cold remedies (Cepie), ophthalmic solutions (Viewclear, AZ), anti-inflammatory/analgesics (ESBIEN S), hemorrhoidal remedies, dermal remedies (Aposty, Dolmycin), quasi-drugs/cosmetics, nutrient tonics, soft drinks/health foods, and foods for specified health uses; as well as beverages like Hepalyse W series. Zeria operates production facilities in Japan (Saitama, Tsukuba, 2nd Tsukuba, IONA's Fukushima), Switzerland (Tillotts Pharma's Ziefen), Denmark (ZPD's Esbjerg), and Vietnam (F.T. Pharma's Cat Lai), with international subsidiaries including Tillotts Pharma AG (Switzerland, gastroenterology focus), ZPD A/S (Denmark), and presence in Europe (Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy), Vietnam, and Denmark targeting healthcare professionals, patients, and consumers primarily in gastroenterology, orthopedics, dermatology, and consumer health segments. Recent developments include the merger with subsidiary Kenso-Seiyaku in April 2025; launch of Veltassa 8.4g powder for suspension for hyperkalemia in March 2025 and Hepalyse W Shine beverage in October 2024; partnership between Tillotts Pharma and Pioneer Pharmaceuticals for marketing and distribution of Asacol Tablets 800mg in China announced in late 2024; agreement with Agastra-Lab for development of Acotiamide in 2024; takeover of manufacturing and marketing approval for Dafclear Tablets (fidaxomicin) from Astellas Pharma in April 2023; and formation of JoinHealth ApS by ZPD A/S and EHP ApS.